Prevalence of clinically manifested drug interactions in hospitalized patients: A systematic review and meta-analysis.
Tâmara Natasha Gonzaga de Andrade SantosGivalda Mendonça da Cruz MacieiraBárbara Manuella Cardoso Sodré AlvesThelma OnozatoGeovanna Cunha CardosoMônica Thaís Ferreira NascimentoPaulo Ricardo Saquete Martins-FilhoDivaldo Pereira de LyraAlfredo Dias de Oliveira-FilhoPublished in: PloS one (2020)
This systematic review showed that, despite the significant prevalence of potential DDIs reported in the literature, less than one in ten patients were exposed to a clinically manifested drug interaction. The use of causality tools to identify clinically manifested DDIs as well as clinical adoption of DDI lists based on actual adverse outcomes that can be identified through the implementation of real DDI notification systems is recommended to reduce the incidence of alert fatigue, enhance decision-making for DDI prevention or resolution, and, consequently, contribute to patient safety.
Keyphrases
- patient safety
- systematic review
- risk factors
- quality improvement
- end stage renal disease
- decision making
- ejection fraction
- newly diagnosed
- chronic kidney disease
- healthcare
- meta analyses
- peritoneal dialysis
- emergency department
- adverse drug
- prognostic factors
- risk assessment
- randomized controlled trial
- single molecule
- human health
- climate change
- patient reported outcomes
- clinical decision support
- physical activity